Foreign body infections due to Staphylococcus epidermidis

Annals of Medicine

Volumn 41, Issue 2, 2009, Pages 109-119

  Uckay, Ilker ^a   Pittet, Didier ^a   Vaudaux, Pierre ^a   Sax, Hugo ^a   Lew, Daniel ^a   Waldvogel, Francis ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Berger Van Berchem and Co   (Switzerland)

Author keywords

Biofilm; Catheter; Foreign body infection; Implant; Staphylococcus epidermidis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; METICILLIN; MINOCYCLINE; OFLOXACIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINUPRISTIN; RIFAMPICIN; SULFADIAZINE SILVER; TEICOPLANIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BIOFILM; BLOODSTREAM INFECTION; CARCINOMA IN SITU; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; DEVICE INFECTION; DEVICE REMOVAL; DRUG HALF LIFE; FOREIGN BODY; FOREIGN BODY INFECTION; HUMAN; IMPLANT; IN VITRO STUDY; INFECTIOUS ARTHRITIS; JOINT PROSTHESIS; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROSTHESIS INFECTION; PROSTHESIS MATERIAL; REVIEW; SILVER IMPREGNATION; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BIOFILMS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FOREIGN BODIES; HUMANS; JOINT PROSTHESIS; PROSTHESIS FAILURE; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 61349134148     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890802337045     Document Type: Review

References (98)

1. Darouiche RO. Treatment of infections associated with surgical implants. New Engl J Med. 2004;350:1422-9.
2. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis. 2001;33 suppl 2:S94-106.
3. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. New Engl J Med. 2004;351:1645-54.
4. Bengtson S. Prosthetic osteomyelitis with special reference to the knee: risks, treatment and costs. Ann Med. 1993;25:523-9.
5. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc. 2006;81:1159-71.
6. Rupp ME, Archer GL. Coagulase-negative staphylococci: pathogens associated with medical progress. Clin Infect Dis. 1994;19:231-43; quiz 44-5.
7. Kloos WE, Bannerman TL. Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev. 1994;7:117-40.
8. Steckelberg JM, Osmon DR. Prosthetic joint infections. In: Bisno AL, Waldvogel FA, editors. Infections associated with indwelling medical devices. 3rd ed. Washington DC: American Society for Microbiology Press; 2000. p. 173-209.
9. Moran E, Masters S, Berendt AR, McLardy-Smith P, Byren I, Atkins BL. Guiding empirical antibiotic therapy in orthopaedics: the microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect. 2007;55:1-7.
10. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet. 2000;355:1864-8.
11. Hugonnet S, Sax H, Eggimann P, Chevrolet JC, Pittet D. Nosocomial bloodstream infection and clinical sepsis. Emerg Infect Dis. 2004;10:76-81.
12. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control. 1999;27:520-32.
13. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27:887-92.
14. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239-44.
15. Hira V, Sluijter M, Estevao S, Horst-Kreft D, Ott A, de Groot R, et al. Clinical and molecular epidemiologic characteristics of coagulase-negative staphylococcal bloodstream infections in intensive care neonates. Pediatr Infect Dis J. 2007;26:607-12.
16. Thylefors JD, Harbarth S, Pittet D. Increasing bacteremia due to coagulase-negative staphylococci: fiction or reality? Infect Control Hosp Epidemiol. 1998;19:581-9.
17. Eggimann P, Pittet D. Overview of catheter-related infections with special emphasis on prevention based on educational programs. Clin Microbiol Infect. 2002;8:295-309.
18. Falcone M, Micozzi A, Pompeo ME, Baiocchi P, Fabi F, Penni A, et al. Methicillin-resistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis and S. aureus. J Chemother. 2004;16:540-8.
19. Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S. Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol. 1999;20:396-401.
20. Haas JP, Evans AM, Preston KE, Larson EL. Risk factors for surgical site infection after cardiac surgery: the role of endogenous flora. Heart Lung. 2005;34:108-14.
21. Whitehouse JD, Sexton D. Epidemiology and pathogenesis of and risk factors for surgical site infection. UpToDate Online. 2007;16:1 (www.ufdol.com).
22. Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis. 1998;26:1182-7.
23. Petrelli D, Zampaloni C, D'Ercole S, Prenna M, Ballarini P, Ripa S, et al. Analysis of different genetic traits and their association with biofilm formation in Staphylococcus epidermidis isolates from central venous catheter infections. Eur J Clin Microbiol Infect Dis. 2006;25:773-81.
24. Gill SR, Fouts DE, Archer GL, Mongodin EF, Deboy RT, Ravel J, et al. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain. J Bacteriol. 2005;187:2426-38.
25. Garrett DO, Jochimsen E, Murfitt K, Hill B, McAllister S, Nelson P, et al. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol. 1999;20:167-70.
26. Mohanty SS, Kay PR. Infection in total joint replacements. Why we screen MRSA when MRSE is the problem? J Bone Joint Surg. 2004;86:266-8.
27. Thore M, Kuhn I, Lofdahl S, Burman LG. Drug-resistant coagulase-negative skin staphylococci. Evaluation of four marker systems and epidemiology in an orthopaedic ward. Epidemiol Infect. 1990;105:95-105.
28. Galdbart JO, Morvan A, Desplaces N, el Solh N. Phenotypic and genomic variation among Staphylococcus epidermidis strains infecting joint prostheses. J Clin Microbiol. 1999;37:1306-12.
29. Van Wijngaerden E, Peetermans WE, Van Lierde S, Van Eldere J. Polyclonal staphylococcus endocarditis. Clin Infect Dis. 1997;25:69-71.
30. Rijnders BJ, Van Wijngaerden E, Van Eldere J, Peetermans WE. Polyclonal Staphylococcus epidermidis intravascular catheter-related infections. Clin Microbiol Infect. 2001;7:388-91.
31. Vaudaux P, Kelley WL, Lew DP. Staphylococcus aureus small colony variants: difficult to diagnose and difficult to treat. Clin Infect Dis. 2006;43:968-70.
32. Adler H, Widmer A, Frei R. Emergence of a teicoplanin-resistant small colony variant of Staphylococcus epidermidis during vancomycin therapy. Eur J Clin Microbiol Infect Dis. 2003;22:746-8.
33. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nature Rev. 2006;4:295-305.
34. Vuong C, Otto M. Staphylococcus epidermidis infections. Microbes Infect. 2002;4:481-9.
35. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest. 2003;112:1466-77.
36. Peters G. Pathogenesis of S. epidermidis foreign body infections. Brit J Clin Prac. 1988;57:62-5.
37. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis. 2001;33:1387-92.
38. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis. 2002;2:677-85.
39. Arciola CR, Baldassarri L, Montanaro L. Presence of icaA and icaD genes and slime production in a collection of staphylococcal strains from catheter-associated infections. J Clin Microbiol. 2001;39:2151-6.
40. Vandecasteele SJ, Van Eldere J, Merckx R, Peetermans WE. The effect of systemic antibiotics on the microbiological diagnosis of experimental foreign body infections caused by Staphylococcus epidermidis. Diag Microbiol Infect Dis. 2004;48:89-95.
41. Lew D, Schrenzel J, Francois P, Vaudaux P. Pathogenesis, prevention, and therapy of staphylococcal prosthetic infections. Curr Clin Top Infect Dis. 2001;21:252-70.
42. Rohde H, Burandt EC, Siemssen N, Frommelt L, Burdelski C, Wurster S, et al. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation of Staphylococcus epidermidis and Staphylococcus aureus isolated from prosthetic hip and knee joint infections. Biomaterials. 2007;28:1711-20.
43. Vandecasteele SJ, Peetermans WE, Carbonez A, Van Eldere J. Metabolic activity of Staphylococcus epidermidis is high during initial and low during late experimental foreign-body infection. J Bacteriol. 2004;186:2236-9.
44. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scot HM. Microbial biofilms. Ann Rev Microbiol. 1995;49:711-45.
45. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771-6.
46. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis. 1990;162:96-102.
47. Vadyvaloo V, Otto M. Molecular genetics of Staphylococcus epidermidis biofilms on indwelling medical devices. Int J Artif Organs. 2005;28:1069-78.
48. Mack D, Davies AP, Harris LG, Rohde H, Horstkotte MA, Knobloch JK. Microbial interactions in Staphylococcus epidermidis biofilms. Anal Bioanal Chem. 2007;387:399-408.
49. Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Invest. 1984;73:1191-200.
50. Johnson GM, Lee DA, Regelmann WE, Gray ED, Peters G, Quie PG. Interference with granulocyte function by Staphylococcus epidermidis slime. Infect Immun. 1986;54:13-20.
51. Bernard L, Vaudaux P, Huggler E, Stern R, Frehel C, Francois P, et al. Inactivation of a subpopulation of human neutrophils by exposure to ultrahigh-molecular-weight polyethylene wear debris. FEMS Immunol Med Microbiol. 2007;49:425-32.
52. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;27:97-132; quiz 3-4; discussion 96.
53. Kaiser AB, Petracek MR, Lea JW, Kernodle DS, Roach AC, Alford WC Jr, et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double-blind trial in 1030 patients. Ann Surg. 1987;206:791-7.
54. Widerstrom M, Monsen T, Karlsson C, Wistrom J. Molecular epidemiology of meticillin-resistant coagulase-negative staphylococci in a Swedish county hospital: evidence of intra- and interhospital clonal spread. J Hosp Infect. 2006;64:177-83.
55. James PJ, Butcher IA, Gardner ER, Hamblen DL. Methicillin-resistant Staphylococcus epidermidis in infection of hip arthroplasties. J Bone Joint Surg. 1994;76:725-7.
56. Zingg W, Demartines N, Ruef C. Reduced susceptibility of coagulase-negative staphylococci in surgical patients after surgical procedures. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 16-19 December 2005. Abstract no. K-1378.
57. Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs. 2006;66:1089-105.
58. Vedel G, Leruez M, Lemann F, Hraoui E, Ratovohery D. Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs. Eur J Clin Microbiol Infect Dis. 1990;9:820-2.
59. Sloos JH, van de Klundert JA, Dijkshoorn L, van Boven CP. Changing susceptibilities of coagulase-negative staphylococci to teicoplanin in a teaching hospital. J Antimicrob Chemother. 1998;42:787-91.
60. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. New Engl J Med. 1992;30:281-6.
61. Mini E, Nobili S, Periti P. Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis? Drugs. 54 suppl. 1997;6:39-52.
62. Cranny G, Elliott R, Weatherly H, Chambers D, Hawkins N, Myers L, et al. A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. Health Technol Assess. 2008;12:iii-iv, xi-xii, 1-147.
63. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249-72.
64. Eggimann P, Hugonnet S, Sax H, Harbarth S, Chevrolet JC, Pittet D. Long-term reduction of vascular access-associated bloodstream infection. Ann Intern Med. 2005;142:875-6.
65. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. New Engl J Med. 2006;355:2725-32.
66. Walder B, Pittet D, Tramer MR. Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis. Infect Control Hosp Epidemiol. 2002;23:748-56.
67. Bernard L, Hoffmeyer P, Assal M, Vaudaux P, Schrenzel J, Lew D. Trends in the treatment of orthopaedic prosthetic infections. J Antimicrob Chemother. 2004;53:127-9.
68. Anagnostakos K, Kelm J, Regitz T, Schmitt E, Jung W. In vitro evaluation of antibiotic release from and bacteria growth inhibition by antibiotic-loaded acrylic bone cement spacers. J Biomed Mater Res B Appl Biomater. 2005;72:373-8.
69. Mandell GL. The antimicrobial activity of rifampin: emphasis on the relation to phagocytes. Rev Infect Dis. 1983;5 suppl 3:S463-7.
70. Monzon M, Oteiza C, Leiva J, Amorena B. Synergy of different antibiotic combinations in biofilms of Staphylococcus epidermidis. J Antimicrob Chemother. 2001;48:793-801.
71. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279:1537-41.
72. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis. 1992;14:1251-3.
73. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother. 1997;39:235-40.
74. Archer GL, Johnston JL, Vazquez GJ, Haywood HB 3rd. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. Rev Infect Dis. 1983;5 suppl 3:S538-42.
75. Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother. 2006;50:55-61.
76. Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother. 2007;51:1556-8.
77. LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant. 2007;22:2239-46.
78. Mogenet I, Raetz-Dillon S, Canonge JM, Archambaud M, Bonnet E. Successful treatment of Staphylococcus epidermidis hip prosthesis infection with oral linezolid. Ann Pharmacother. 2004;38:986-8.
79. Saleh-Mghir A, Ameur N, Muller-Serieys C, Ismael F, Lemaitre F, Massias L, et al. Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother. 2002;46:1122-4.
80. Isiklar ZU, Darouiche RO, Landon GC, Beck T. Efficacy of antibiotics alone for orthopaedic device related infections. Clin Orthop Relat Res. 1996;332:184-9.
81. Gagnon RF, Richards GK, Kostiner GB. Time-kill efficacy of antibiotics in combination with rifampin against Staphylococcus epidermidis biofilms. Adv Perit Dial. 1994;10:189-92.
82. Soriano A, Jurado A, Marco F, Almela M, Ortega M, Mensa J. In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis]. Rev Esp Quimioter. 2005;18:168-72.
83. Lemmen SW, Hafner H, Klik S, Lutticken R, Zolldann D. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae. Chemotherapy. 2003;49:33-5.
84. Simon A, Bode U, Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. Clin Microbiol Infect. 2006;12:606-20.
85. Sherertz RJ, Boger MS, Collins CA, Mason L, Raad II. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Chemother. 2006;50:1865-8.
86. Vercaigne LM, Sitar DS, Penner SB, Bernstein K, Wang GQ, Burczynski FJ. Antibiotic-heparin lock: in vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy. 2000;20:394-9.
87. Lee JY, Ko KS, Peck KR, Oh WS, Song JH. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. J Antimicrob Chemother. 2006;57:1110-5.
88. Rubin LG, Shih S, Shende A, Karayalçin G, Lanzkowsky P. Cure of implantable venous port-associated bloodstream infections in pediatric hematology-oncology patients without catheter removal. Clin Infect Dis. 1999;29:102-5.
89. Yao Y, Sturdevant DE, Villaruz A, Xu L, Gao Q, Otto M. Factors characterizing Staphylococcus epidermidis invasiveness determined by comparative genomics. Infect Immun. 2005;73:1856-60.
90. Balaban N, Giacometti A, Cirioni O, Gov Y, Ghiselli R, Mocchegiani F, et al. Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis. 2003;187:625-30.
91. Nakamoto DA, Rosenfield ML, Haaga JR, Merritt K, Sachs PB, Hutton MC, et al. In vivo treatment of infected prosthetic graft material with urokinase: an animal model. J Vasc Interv Radiol. 1994;5:549-52.
92. Cerca N, Oliveira R, Azeredo J. Susceptibility of Staphylococcus epidermidis planktonic cells and biofilms to the lytic action of staphylococcus bacteriophage K. Lett Appl Microbiol. 2007;45:313-7.
93. Carmen JC, Roeder BL, Nelson JL, Beckstead BL, Runyan CM, Schaalje GB, et al. Ultrasonically enhanced vancomycin activity against Staphylococcus epidermidis biofilms in vivo. J Biomater Appl. 2004;18:237-45.
94. van der Borden AJ, van der Mei HC, Busscher HJ. Electric block current induced detachment from surgical stainless steel and decreased viability of Staphylococcus epidermidis. Biomaterials. 2005;26:6731-5.
95. Wayne, PA. Performance standards for antimicrobial susceptibility testing. CLSI. 2007 (www.clsi.org).
96. Evans RC, Holmes CJ. Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicrob Agents Chemother. 1987;31:889-94.
97. Pascual A, Ramirez de Arellano E, Perea EJ. Activity of glycopeptides in combination with amikacin or rifampin against Staphylococcus epidermidis biofilms on plastic catheters. Eur J Clin Microbiol Infect Dis. 1994;13:515-7.
98. Peck KR, Kim SW, Jung SI, Kim YS, Oh WS, Lee JY, et al. Antimicrobials as potential adjunctive agents in the treatment of biofilm infection with Staphylococcus epidermidis. Chemotherapy. 2003;49:189-93.